Study to gauge effectiveness of product aimed at diarrhea in foals

Spread the word
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

An animal health company says it is planning a study to assess the effectiveness of an equine formulation in combination with a probiotic for use in foals with loose or watery diarrhea.

Jaguar Animal Health said the study would determine the safety, tolerability, and efficacy of its Neonorm Foal Plus, an equine formulation of its actively marketed Neonorm Calf product.

Neonorm Foal Plus consists of a standardized botanical extract, which it has trademarked as Neonorm, in combination with a third-party probiotic.

The randomized, multi-site, blind-controlled study will assess the product when given orally in a paste formulation. About 60 foals would be enrolled in the six-day study, which will take place in Argentina, where it is currently foaling season.

“Although probiotics are commonly used in foals, there are currently no anti-secretory products commercially available for the foal market,” Jaguar’s chief executive and president, Lisa Conte, said.

She said the company believed the combination of probiotics with Neonorm would produce a new and highly effective standard of care for the management of gut health, stool formation and the normalization of hydration in foals.

The company hoped to launch the product commercially in December, during the American Association of Equine Practitioners Trade Show in Las Vegas.

Diarrhea is among the most common clinical complaints in foals and often takes place in the first 30 days following birth.

Neonorm Calf, the company’s lead non-prescription product, contains the same standardized botanical extract as Neonorm Foal Plus and has been clinically shown to assist normalization of stool formation and ion and water flow in the lumen of preweaned dairy calves.

The Neonorm standardized botanical extract is derived from the Croton lechleri tree, which is sustainably harvested.

Jaguar has filed nine Investigational New Animal Drug applications with the US Food and Drug Administration and intends to develop species-specific formulations of Neonorm in six additional target species.

  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Leave a Reply